company background image
5269

Venus Remedies BSE:526953 Stock Report

Last Price

₹240.10

Market Cap

₹3.2b

7D

-0.2%

1Y

-23.6%

Updated

23 May, 2022

Data

Company Financials
526953 fundamental analysis
Snowflake Score
Valuation5/6
Future Growth0/6
Past Performance4/6
Financial Health6/6
Dividends0/6

526953 Stock Overview

Venus Remedies Limited develops and markets pharmaceutical products in India and internationally.

Venus Remedies Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Venus Remedies
Historical stock prices
Current Share Price₹240.10
52 Week High₹638.50
52 Week Low₹204.35
Beta1.45
1 Month Change-23.00%
3 Month Change-11.04%
1 Year Change-23.62%
3 Year Change637.63%
5 Year Change155.97%
Change since IPO533.51%

Recent News & Updates

Shareholder Returns

526953IN PharmaceuticalsIN Market
7D-0.2%2.9%2.1%
1Y-23.6%-10.3%8.6%

Return vs Industry: 526953 underperformed the Indian Pharmaceuticals industry which returned -9.5% over the past year.

Return vs Market: 526953 underperformed the Indian Market which returned 9.5% over the past year.

Price Volatility

Is 526953's price volatile compared to industry and market?
526953 volatility
526953 Average Weekly Movement10.1%
Pharmaceuticals Industry Average Movement6.6%
Market Average Movement7.0%
10% most volatile stocks in IN Market9.7%
10% least volatile stocks in IN Market4.6%

Stable Share Price: 526953 is more volatile than 90% of Indian stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: 526953's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Indian stocks.

About the Company

FoundedEmployeesCEOWebsite
1989837Ashutosh Jainhttps://www.venusremedies.com

Venus Remedies Limited develops and markets pharmaceutical products in India and internationally. The company offers its products in various therapeutic areas, such as analgesic, analgesic and antipyretic, anti-diabetic, antibiotic, anticoagulant, cardiac, disinfectant and antiseptic, gastro therapy, hand sanitizers, hormones, iron supplements, neurology, oncology, pain management, respiratory, skin care, stress reliever, urology, vitamins/minerals/nutrients, and wound management. Venus Remedies Limited was incorporated in 1989 and is based in Panchkula, India.

Venus Remedies Fundamentals Summary

How do Venus Remedies's earnings and revenue compare to its market cap?
526953 fundamental statistics
Market Cap₹3.21b
Earnings (TTM)₹756.00m
Revenue (TTM)₹5.70b

4.2x

P/E Ratio

0.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
526953 income statement (TTM)
Revenue₹5.70b
Cost of Revenue₹3.65b
Gross Profit₹2.05b
Other Expenses₹1.29b
Earnings₹756.00m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

May 27, 2022

Earnings per share (EPS)56.56
Gross Margin35.94%
Net Profit Margin13.26%
Debt/Equity Ratio9.9%

How did 526953 perform over the long term?

See historical performance and comparison

Valuation

Is Venus Remedies undervalued compared to its fair value and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: 526953 (₹240.1) is trading below our estimate of fair value (₹1154.7)

Significantly Below Fair Value: 526953 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 526953 is good value based on its PE Ratio (4.2x) compared to the Indian Pharmaceuticals industry average (21.5x).

PE vs Market: 526953 is good value based on its PE Ratio (4.2x) compared to the Indian market (20.5x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 526953's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 526953 is good value based on its PB Ratio (0.7x) compared to the IN Pharmaceuticals industry average (2.7x).


Future Growth

How is Venus Remedies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


20.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Venus Remedies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Venus Remedies performed over the past 5 years?

Past Performance Score

4/6

Past Performance Score 4/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


75.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 526953 has a large one-off gain of ₹205.5M impacting its December 31 2021 financial results.

Growing Profit Margin: 526953's current net profit margins (13.3%) are higher than last year (4%).


Past Earnings Growth Analysis

Earnings Trend: 526953 has become profitable over the past 5 years, growing earnings by 75.2% per year.

Accelerating Growth: 526953's earnings growth over the past year (255.3%) exceeds its 5-year average (75.2% per year).

Earnings vs Industry: 526953 earnings growth over the past year (255.3%) exceeded the Pharmaceuticals industry 12.5%.


Return on Equity

High ROE: 526953's Return on Equity (17.4%) is considered low.


Financial Health

How is Venus Remedies's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 526953's short term assets (₹2.9B) exceed its short term liabilities (₹1.3B).

Long Term Liabilities: 526953's short term assets (₹2.9B) exceed its long term liabilities (₹464.1M).


Debt to Equity History and Analysis

Debt Level: 526953's net debt to equity ratio (0.4%) is considered satisfactory.

Reducing Debt: 526953's debt to equity ratio has reduced from 79.2% to 9.9% over the past 5 years.

Debt Coverage: 526953's debt is well covered by operating cash flow (158.3%).

Interest Coverage: 526953 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Venus Remedies's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 526953's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 526953's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 526953's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 526953's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: 526953 is not paying a notable dividend for the Indian market.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 526953 has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Ashutosh Jain (44 yo)

no data

Tenure

₹4,195,958

Compensation

Mr. Ashutosh Jain, B.A., LL B serves as Chief Executive Officer at Venus Remedies Limited. He has been an Executive Director of Venus Remedies Ltd.since May 2007 and serves as its Head of Legal, Regulator...


CEO Compensation Analysis

Compensation vs Market: Ashutosh's total compensation ($USD53.93K) is above average for companies of similar size in the Indian market ($USD38.56K).

Compensation vs Earnings: Ashutosh's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: 526953's management team is considered experienced (2.3 years average tenure).


Board Members

Experienced Board: 526953's board of directors are seasoned and experienced ( 15 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.3%.


Top Shareholders

Company Information

Venus Remedies Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Venus Remedies Limited
  • Ticker: 526953
  • Exchange: BSE
  • Founded: 1989
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₹3.209b
  • Shares outstanding: 13.37m
  • Website: https://www.venusremedies.com

Number of Employees


Location

  • Venus Remedies Limited
  • Plot 51-52, Industrial Area
  • Phase-1
  • Panchkula
  • Haryana
  • 134113
  • India

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/23 00:00
End of Day Share Price2022/05/23 00:00
Earnings2021/12/31
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.